FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

The evacuation order has cut off the coastal area of Al Mawasi, where thousands of Palestinians are living in tents, from the ...

E! News sits down with the cast of ‘Freakier Friday’ including Lindsay Lohan and she revealed the hilarious way her ...

Haya suffered from complications at birth, her mother said, due to a lack of oxygen. The baby's weak immune system at birth ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach ...

Cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to ...

Traffic deaths in New York City have dropped to historic lows, but some worry the city's actions could reverse that progress.

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...